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Abstract: We characterized metabolic changes along the cortico-spinal tract (CST) in multiple sclerosis
(MS) patients using a novel application of chemical shift imaging (CSI) and considering the spatial var-
iation of metabolite levels. Thirteen relapsing-remitting (RR) and 13 primary-progressive (PP) MS
patients and 16 controls underwent 1H-MR CSI, which was applied to coronal-oblique scans to sample
the entire CST. The concentrations of the main metabolites, i.e., N-acetyl-aspartate, myo-Inositol (Ins),
choline containing compounds (Cho) and creatine and phosphocreatine (Cr), were calculated within
voxels placed in regions where the CST is located, from cerebral peduncle to corona radiata. Differen-
ces in metabolite concentrations between groups and associations between metabolite concentrations
and disability were investigated, allowing for the spatial variability of metabolite concentrations in the
statistical model. RRMS patients showed higher CST Cho concentration than controls, and higher CST
Ins concentration than PPMS, suggesting greater inflammation and glial proliferation in the RR than in
the PP course. In RRMS, a significant, albeit modest, association between greater Ins concentration and
greater disability suggested that gliosis may be relevant to disability. In PPMS, lower CST Cho and Cr
concentrations correlated with greater disability, suggesting that in the progressive stage of the disease,
inflammation declines and energy metabolism reduces. Attention to the spatial variation of metabolite
concentrations made it possible to detect in patients a greater increase in Cr concentration towards the
superior voxels as compared to controls and a stronger association between Cho and disability, sug-
gesting that this step improves our ability to identify clinically relevant metabolic changes. Hum Brain
Mapp 35:993–1003, 2014. VC 2012 The Authors. Human Brain Mapping Published by Wiley Periodicals, Inc.
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INTRODUCTION
An increasing number of studies using quantitative
magnetic resonance (MR) techniques have focused on
detecting damage in the normal-appearing brain tissue
[Chard et al., 2002; Khaleeli et al., 2007, 2008; Sastre-Gar-
riga et al., 2005; Tiberio et al., 2006; Tur et al., 2011] with
the ultimate goal of understanding the mechanisms
accounting for the development of irreversible disability in
multiple sclerosis (MS). 1H-MR spectroscopy (MRS) is
amongst the most pathologically specific techniques, since
it allows in vivo quantification of the concentrations of the
most abundant metabolites [Chard et al., 2002; Sastre-Gar-
riga et al., 2005; Tiberio et al., 2006], which reflect the
underlying pathological processes. In particular, MRS
allows quantification not only of N-acetyl-aspartate
(NAA), which is a marker of neuronal health and integrity
[Moffett et al., 2007], but also of other important metabo-
lites, such as myo-inositol (Ins) and choline (Cho), which
reflect glial proliferation (and activation) and membrane
turnover associated with inflammation [Bitsch et al., 1999],
respectively. Abnormal concentrations of metabolites,
including NAA and Ins, have been reported in the brain
[Chard et al., 2002; Sastre-Garriga et al., 2005; Tiberio
et al., 2006] and spinal cord [Ciccarelli et al., 2007; Marliani
et al., 2007, 2010] of patients with MS when compared
with controls, and are associated with motor disability
[Chard et al., 2002; Sastre-Garriga et al., 2005] and cogni-
tive impairment [Summers et al., 2008].
Many spectroscopy studies have investigated relatively
large volumes in the central nervous system (CNS) using
chemical-shift imaging (CSI), which permits excitation of a
large spectroscopic volume located on axial slices and col-
lects the spectral data from many voxels [Chard et al.,
2002; Sastre-Garriga et al., 2005]. The reported metabolite
concentrations, therefore, represent an ‘‘averaged’’ concen-
tration over different CNS locations and tissues [Barker
et al., 2006]. On the other hand, single-voxel MRS has been
successfully used to quantify metabolites at specific loca-
tions in the brain white matter (WM) [Fernando et al.,
2004] and gray matter (GM) [Geurts et al., 2004], providing
little information on the spatial distribution of metabolites.
Here, we localized CSI on a coronal slice passing through
the cortico-spinal tract (CST) in order to investigate meta-
bolic changes along the entire motor pathway, from the in-
ternal capsule to the corona radiata in patients with
different types of MS within a single acquisition protocol.
We hypothesized that patients with primary-progressive
MS (PPMS) would show lower NAA and Cho than
relapsing-remitting MS (RRMS), suggesting greater axonal
damage [Tallantyre et al., 2009] and less inflammatory de-
myelination [Bramow et al., 2010]. To understand whether
metabolic changes were clinically relevant, the associations
between metabolite concentrations and disability were
investigated in each patient group. This study builds on
previous work, which has demonstrated that CST structural
abnormalities detected by MRI have a direct impact on the
motor deficits observed in patients with MS [Gorgoraptis
et al., 2010; Lee et al., 2000; Reich et al., 2007]. Since it has
been recently suggested that the ability to detect pathologi-
cal differences between MS patients and healthy controls
may be significantly increased by accounting for spatial
variation of imaging measures from one end of a tract to
the other [Goldsmith et al., 2011], we have repeated our
analysis by taking into account the variability of metabolite
concentrations that is attributed to the specific location of
the voxel within the CST.
METHODS
Subjects and Clinical Assessment
Thirteen consecutive patients with RRMS [Lublin and
Reingold, 1996], 13 patients with PPMS [Thompson et al.,
2000], and 16 healthy controls were invited to participate
in this study, which was approved by the Ethics Commit-
tee of the National Hospital for Neurology and Neurosur-
gery and UCL Institute of Neurology; all participants gave
written informed consent.
All patients were scored on the expanded disability sta-
tus scale (EDSS) [Kurtzke, 1983], timed walk test (TWT)
and nine-hole peg test (NHPT) [Cutter et al., 1999]. Those
patients who were not able to walk were assigned a TWT
score of 180 s and those patients who were not able to
complete the NHPT were assigned a NHPT score of 300 s
[Hoogervorst et al., 2002].
MRI Protocol
All subjects underwent the following MR protocol on a
GE 1.5T scanner:
(i) T1-weighted 3D FSPGR (coronal-oblique) imaging (TE
5.104 ms, TR 14.3 ms, TI (inversion time) 450 ms,
NEX 1, image dimensions 128  256, voxel size 1.2
 1.2  1.2 mm3).
(ii) Dual-echo fast spin echo (FSE) axial and coronal-
oblique imaging (TE 17 ms, TR 2500, NEX 1, num-
ber of echoes 2, voxel dimensions 0.9  0.9  5
mm3). The coronal-oblique images in (ii) and (iii) were
acquired perpendicularly to the main axis (i.e., top) of
the corpus callosum. In this way, the chemical shift
imaging (CSI) grid (see Fig. 1) covered the entire CST
with a single 2D spectroscopy protocol [see (iii)].
(iii) 1H-MR volume-selective CSI 2D sequence with a point
resolved spectroscopy localization scheme (PRESS), to
acquire data from a volume located on a coronal-
oblique scan to image the CST along its main axis (Fig.
1) (TE 30 ms, TR 3000 ms, number of excitations 1, sec-
tion thickness 15 mm, 24  24 phase encoding steps
over a field of view of 220  220 mm, 512 points, nomi-
nal single voxel volume of 1.26 ml). To optimize the
magnetic field homogeneity, local shimming was per-
formed, using the water signal in the absence of any
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suppression. Afterwards, to achieve water suppression,
a chemical shift selective saturation pulse (CHESS) was
used. Finally, the unwanted signal from lipids was
eliminated by means of outer volume saturation bands,
positioned adjacent to the edges of the PRESS-selected
volume. Throughout the study, we performed a quality
assurance (QA) programme that involved a phantom
containing known concentration of NAA (50 mmol),
using a single voxel PRESS protocol, and the ‘‘Braino’’
phantom (GE Medical Systems, Milwaukee, WI), con-
taining 12.5 mM of NAA, 10 mM of Cr, 3 mM of Ch,
7.5 mM of ml, 12.5 mM of Glu, 5 mM of Lac, sodium
azide (0.1%), 50 mM of potassium phosphate monoba-
sic (KH2PO4), 56 mM of sodium hydroxide (NaOH)
and 1 ml/l of Gd-DPTA (Magnevist), using the CSI
PRESS protocol. This QA routine allowed us to confirm
the stability of the measurements and to obtain the cali-
bration factor, which was then used in the LCModel
analysis for metabolite quantification.
Image Analysis
Lesions were contoured on the 13 T1-weighted images
that corresponded to the spectroscopic grid, using the FSE
images as reference, with DispImage (D.L. Plummer, Uni-
versity College of London, London, UK) [Plummer, 1992;
Sailer et al., 1999]. T1-images were then segmented into
WM, GM, cerebrospinal fluid (CSF), and lesions, using
SPM8 (Functional Imaging Laboratory, Wellcome Depart-
ment of Imaging Neuroscience, London).
MRS imaging data were processed using SAGE–IDL
2005.3 (GE, Milwaukee). First, five voxels were selected and
placed by an experienced observer (C.T.) on each side of the
brain, one above the other, without overlapping, in five
regions of the white matter where the CST is known to be
located [i.e., cerebral peduncle, above the cerebral peduncle,
internal capsule, above the internal capsule, corona radiata
(Fig. 2)]. This step was performed using the anatomical land-
marks visible on the coronal proton-density images and with
reference to both the individual T1-weighted images and the
JHU tractography-atlas (www.fmrib.ox.ac.uk/fsl/), which
was used to display the CST (Fig. 2). Secondly, voxels were
extracted from the spectroscopic grid, one at a time, and the
segmented WM, GM, CSF and lesional tissue within each
voxel, were obtained. A fraction for each segment was then
calculated and retained to be used as covariates in the statis-
tical analysis. Finally, using the LCModel (Version 5.2-1)
[Provencher, 1993], metabolite quantification in mmol/l was
obtained within the extracted voxels. In particular, the con-
centrations of NAA plus N-acetyl-aspartyl-glutamate
(tNAA), choline-containing compounds (Cho), creatine and
phosphocreatine (Cr), and myo-inositol (Ins) were obtained
and retained only if their associated SD was <20%.
The number of voxels used in the following steps of the
analysis was 398 for tNAA (151, 121, and 126 for controls,
RRMS and PPMS, respectively); 353 for Cho (129, 108, and
116, for controls, RRMS and PPMS, respectively); 356 for
Cr (132, 106, and 118, for controls, RRMS and PPMS,
respectively); 213 for Ins (73, 64, and 76, respectively).
Statistical Analysis
In the patient and control group, we tested for differen-
ces in metabolite concentrations between right and left
voxels using the Wilcoxon’s test.
Figure 1.
Chemical shift imaging grid covering the entire CST on a single
image shown together with a schematic picture of the anatomy
of the CST and a spectrum. (A) Coronal brain image, from the
20th U.S. edition of Gray’s Anatomy of the Human Body (20th
edition, thoroughly revised and re-edited by Warren H. Lewis,
Illustrated with 1247 engravings. Philadelphia: Lea & Febiger,
1918, published in 1918); (B) CSI grid covering the entire CST
on a single (FSE) image. This grid shows the original location of
voxels; (C) Spectrum from the voxel located above the left
cerebral peduncle in a healthy control. CSI, Chemical shift imag-
ing; tNAA, N-acetylaspartate and N-acetlylaspartylglutamate;
Glx, glutamate plus glutamine (data not reported); Cr, creatine
and phosphocreatine; Cho, choline-containing compounds; Ins,
myo-inositol.
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Differences Between Groups
Linear mixed regression models were used to detect
differences in the metabolite concentrations between (i)
RRMS and PPMS patients, (ii) each patient group and con-
trols. The metabolite concentration was used as the
dependent variable, and a variable indicating the subject
group as explanatory variable, adjusting for age, gender,
WM, CSF, and lesion fractions, and side (e.g., left or right).
The variables that significantly contributed to explaining
the variance in the dependent variable were retained in
the final model. For each metabolite, all the available
voxels were examined at the same time. This was a con-
servative statistical approach, which reduced the risk of
obtaining sporadic results and false positives.
To investigate whether attention to the spatial variation
of the metabolite concentrations along the CST improved
the ability of the statistical model to detect differences
between groups, the analysis was repeated by including a
variable indicating the position of the voxel; whenever
there was evidence of a linear effect of position, this vari-
able was kept in the model; otherwise, we included in the
model a set of five indicators of position, one for each
voxel. To investigate the effect of the spatial variation on
the differences in metabolite levels between groups, we
repeated the analysis by also modeling the interaction
between group and voxel location.
Association Between Metabolite
Concentrations and Disability
To investigate the association between metabolite con-
centrations and clinical scores in patients, the linear mixed
regression models described above were used with the
addition of an explanatory variable indicating the level of
disability. For the EDSS, an indicator of two EDSS catego-
ries [e.g., EDSS below and above (or equal to) 4.5] was
included. The 4.5 cut-off for the EDSS was chosen based
on the median EDSS for the whole group (Table I). For the
other clinical variables, we used the inverse values of
TWT and NHPT (given their non-normal distribution),
which were entered, in turn, as independent variables. To
assess whether attention for the spatial variation of metab-
olite levels improved our ability to detect associations
between metabolite concentrations and clinical measures,
Figure 2.
Voxels extracted from the spectroscopic grid to obtain concen-
trations of metabolites along the cortico-spinal tract. (A and B)
Probability map of the left and right cortico-spinal tracts, pro-
vided by the JHU white matter tractography atlas (www.fmri-
b.ox.ac.uk/fsl), which were used, together with the individual T1
images, as reference images to identify and position the voxels
along the CST. (C and D) Spectroscopic voxels (in white, 1 ¼
cerebral peduncle, 2 ¼ above cerebral peduncle, 3 ¼ internal
capsule, 4 ¼ above internal capsule, 5 ¼ corona radiata) selected
in the left (C) and right (D) white matter in regions where the
CST is known to be located, from the cerebral peduncle to the
corona radiata, overlaid onto coronal PD images.
r Tur et al. r
r 996 r
the analysis was repeated by including the variable indi-
cating the position of the voxel.
RESULTS
No significant differences were found between the left
and right voxels, for all groups across all metabolite
concentrations.
Differences Between Groups
As expected, patients with PPMS were older, more
disabled, especially in their ability to walk, and with a lon-
ger disease duration, than patients with RRMS (Table I).
The WM was the main tissue within the spectroscopic
voxels (the mean fraction of WM across all voxels was of
87.5% in patients and 91.1% in controls). In patients, the
mean fractions of GM and lesional tissue were 5.3% and
3.5%, respectively.
After correcting for age, gender, voxel tissue contents,
and side, RRMS patients showed a significantly higher
Cho concentration in the CST than healthy controls (P ¼
0.039) and a trend towards a higher Cho concentration
than PPMS patients (P ¼ 0.081) (Table II and Fig. 3); they
also showed a significantly higher CST Ins concentration
than PPMS (P ¼ 0.037) and a trend towards a higher CST
Ins concentration than controls (P ¼ 0.087) (Table II and
Fig. 3). No other significant differences between groups in
metabolite concentrations were observed.
When spatial variation was taken into consideration,
differences in Cr concentrations between patients and
controls became significant, independently from GM, WM,
and lesion fractions within voxels. Both RRMS and PPMS
patients showed a significant (linear) increase in Cr con-
centration from the cerebral peduncle to the corona
radiata: in RRMS, there was a mean increase per voxel
proximity to corona radiata of 0.341 mmol/l [95% Confi-
dence interval (95% CI) 0.095, 0.588], P ¼ 0.007; in PPMS,
TABLE II. Metabolite concentrations and differences
between groups
Metabolites
Mean (SD) mmol/la
Controls RRMS PPMS
tNAA 10.658 (1.186) 10.286 (0.746) 10.105 (0.919)
Cho 1.793 (0.199) 1.938 (0.136)b 1.762 (0.313)
Cr 6.080 (0.387) 6.294 (0.626) 6.054 (1.076)
Ins 5.864 (0.809) 8.142 (5.734)c 5.711 (0.896)
tNAA, N-acetylaspartate and N-acetlylaspartylglutamate; Cho,
choline-containing compounds; Cr, creatine and phosphocreatine;
Ins, myo-inositol.
aThis table shows the mean value (and SD) of each metabolite
concentration for each group of subjects. Each subject contributed
to mean of the appropriate group with one number, representing
the mean value of each metabolite concentration within each sub-
ject, regardless of voxel position along the CST; note that these
values do not correspond to the tNAA mean values used in the
statistical analysis, which were the individual values per subject
per position.
bDifference between RRMS and controls: P ¼ 0.039.
cDifference between RRMS and PPMS P ¼ 0.037 (after adjusting
for age, gender, and voxel tissue contents).
TABLE I. Clinical and demographical characteristics of the subjects
Patients
RRMS vs. PPMS
Controls
Patients vs. controls
All patients RRMSa PPMSa P P
Age (yr)
mean 49.615 45.615 53.615 <0.001b 40.375 <0.001b
SD (range) 12.189 (21, 67) 11.704 (21, 67) 11.361 (30, 65) 12.856 (26, 65)
EDSS
median (range) 4.240 (2, 7.500) 4 (2, 6) 5 (2.500, 7.500) <0.001c – –
TWT (s)
mean 22.685 7.710 36.508 <0.001b – –
SD (range) 46.771 (4.760, 180) 2.245 (4.9, 12) 61.779 (4.760, 180)
HPT (s)
mean 36.772 35.540 37.910 0.310b – –
SD (range) 37.548
(18.870, 162.710)
37.510
(19.590, 158.570)
37.690
(18.870, 62.710)
Disease
duration (yr)
mean 10.160 7.770 12.750 <0.001b – –
SD (range) 7.820 (1, 27) 7.700 (1, 25) 7.110 (3, 27)
aAll the RRMS, but none of the PPMS patients, were on disease modifying treatment. None of the patients had received corticosteroid
treatment over the three months prior to the study.
bt-test
cTwo-sample Wilcoxon rank-sum (Mann–Whitney) test.
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there was a mean increase per voxel proximity to corona
radiata of 0.265 [(95%CI) 0.048, 0.482], P ¼ 0.017. Instead,
this increase in Cr concentration was not seen in controls
(Fig. 4). In fact, all patients together showed a greater
increase in Cr concentration towards the voxels positioned
superiorly compared with controls (Interaction coef. (95%
CI) 0.32 (0.06, 0.60), P ¼ 0.015) (Fig. 4). All patients
together showed a mean increase in tNAA concentration
along the CST from the inferior regions to the corona radi-
ate of 0.634 mmol/l [(95% CI) 0.462, 0.805] P < 0.001;
controls showed an increase of 0.619 mmol/l [(95% CI)
0.381, 0.858], P < 0.001 (Fig. 5); this increase in tNAA con-
centration was not significantly different between groups
(P ¼ 0.921), and was significant even when correcting for
WM fraction change across the CST, which, in turn,
showed, in all subjects together, a significant increase
towards the voxels located in the corona radiata of 0.031
[(95% CI) 0.021, 0.042] P < 0.001. The other metabolites
did not show a significant spatial variation along the CST
Figure 3.
Differences in Cho and Ins between patients and controls. (A)
A significantly lower concentration (in mmol/l) of Cho was seen
in controls when compared to RRMS, and (B) lower Ins (in
mmol/l) was seen in PPMS when compared to RRMS. RRMS,
relapsing-remitting multiple sclerosis; PPMS, primary progressive
multiple sclerosis; Cho, Choline containing compounds (Cho);
Ins, Myo-Inositol.
Figure 4.
Differences between patients and controls in the slope of Cr
along the CST. Both groups of patients showed a significant
increase of Cr concentration (in mmol/l) towards the upper parts
of the CST (for RRMS: P ¼ 0.007; for PPMS: P ¼ 0.017), whereas
controls did not show such increase (P ¼ 0.791). The slope of Cr
significantly differed between patients and controls (P ¼ 0.015),
whilst it did not change between RRMS and PPMS (P ¼ 0.631).
Figure 5.
Predicted tNAA concentrations within a voxel. Both patients
and controls showed a significant increase of tNAA concentra-
tion (in mmol/l) towards the upper parts of the CST after
adjusting for age, gender, and WM content within a voxel
(patients: P < 0.001; controls: P < 0.001). However, this
increase was not significantly different between patients and
controls. Voxel location: 1 ¼ cerebral peduncle, 2 ¼ above cer-
ebral peduncle, 3 ¼ internal capsule, 4 ¼ above internal capsule,
5 ¼ corona radiata. CI, confidence interval; CST, cortico-spinal
tract; RC, regression coefficient; t-NAA, N-acetyl-aspartate plus
N-acetyl-aspartyl-glutamate; WM, white matter.
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and the differences in their concentration between groups
were not affected by accounting for their spatial variation.
Associations Between Metabolite
Concentrations and Disability
In the whole group of patients, lower CST Cho concen-
trations were associated with worse walking ability, as
measured by the TWT scores. Thus, there was a mean
increase in Cho concentration of 1.538 mmol/l [Regression
coefficient, RC (95% CI) 1.538 (0.064, 3.011), P ¼ 0.041] per
unit of higher inverse TWT (in 1/s). When spatial variation
was taken into account, the association between TWT
scores and Cho concentrations became slightly stronger:
there was a mean increase in Cho concentration of 1.664
mmol/l [RC (95% CI) 1.664 (0.274, 3.054), P ¼ 0.019], per
unit of higher inverse TWT (in 1/s) (Fig. 6).
In the PPMS group, lower concentrations of Cho and Cr
in the CST were associated with higher EDSS: per each
EDSS point increase there was a decrease in Cho concentra-
tion of 0.348 mmol/l [RC (95% CI) 0.348 (0.602, 0.094),
P ¼ 0.007], and a decrease in Cr concentration of 0.990
mmol/l [RC (95% CI) 0.990 (1.841, 0.138), P ¼ 0.023]
(Fig. 7A,B). When spatial variation was taken into account,
no major improvements in the strength of the associations
were observed for Cho [RC (95% CI) 0.362 (0.609,
0.115), P ¼ 0.004] or Cr [RC (95% CI) 0.806 (1.595,
0.0163), P ¼ 0.045].
Figure 6.
Association between Cho concentration in the CST and ability
to walk before and after adjusting for the spatial variability of
Cho concentrations along the CST. Patients with reduced ability
to walk (as measured byt the inverse of TWT) showed lower
concentrations of Cho (in mmol/l) in the CST (P ¼ 0.019); (A)
shows this relationship using the raw, unadjusted concentrations
of Cho; (B) shows this relationship using the predicted mean
Cho concentrations ( one SD) after adjusting for age, gender,
tissue fractions, and spatial variation (voxel location and side).
Figure 7.
Association between metabolite concentrations and disability. PPMS
patients with higher disability (as measured by the EDSS) showed
lower concentrations of Cho (A) and Cr (B) in the CST (see text
for more details on these relationships). Here, values of Cr and
Cho concentrations refer to those obtained considering all CST
voxels (left and right). All concentrations are expressed in mmol/l.
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In RRMS patients, higher Ins concentrations were associ-
ated with worse walking performance, as measured by
TWT: there was an increase in Ins concentration of 17.08
mmol/l per unit of lower inverse TWT (in 1/s) [RC (95%
CI) 17.08 (31.95, 2.22), P ¼ 0.024]. No improvement in
this association was observed when spatial variation was
taken into account.
DISCUSSION
We used coronal-oblique CSI to sample metabolite con-
centrations along voxels placed in the WM where the CST
is known to be located, and found that metabolic abnor-
malities occurred in patients with MS when compared
with healthy controls. More specifically, we found a signif-
icantly higher Cho concentration in RRMS than in controls,
who showed similar Cho concentrations to PPMS. We also
found a significantly higher Ins concentration in RRMS
than in PPMS, who showed a similar concentration to con-
trols. When considering the pathological processes that
have been associated with an increase in Cho and Ins
[Bitsch et al., 1999; Kirov et al., 2009; Pan et al., 1996],
these findings would be compatible with more extensive
inflammation with increased membrane turnover [Frischer
et al., 2009; Kirov et al., 2009], and greater glial hyperpla-
sia and proliferation in the CST of patients with RRMS.
These results extend previous investigations, which have
reported increased levels of Ins in all disease types, includ-
ing RR [Chard et al., 2002; Geurts et al., 2004; Marliani
et al., 2010; Vrenken et al., 2005] and PPMS [Geurts et al.,
2006; Sastre-Garriga et al., 2005; Vrenken et al., 2005], by
directly comparing these two clinical types of MS, and by
focusing the investigation on the CST, which mediates
motor function, and its damage has been reported to be
crucial for the development of disability in MS [Bodini
et al., 2009; Giorgio et al., 2010; Gorgoraptis et al., 2010;
Pagani et al., 2005; Tallantyre et al., 2009].
An interesting finding of our study is that attention for
spatial variation of the metabolite concentrations improved
the detection of differences in metabolite levels between
patients and controls. In particular, when taking into
account the spatial variation in the statistical models,
patients showed a greater increase in Cr concentration
towards the superior parts of the CST as compared with
controls. This steady and linear increase in Cr levels
observed in patients could be interpreted as a metabolic
response to structural tissue damage occurring in the CST
[Gorgoraptis et al., 2010; Lee et al., 2000; Reich et al.,
2007]. Increased Cr (e.g., the sum of phosphocreatine and
creatine) may reflect increased energy metabolism [Hajek
and Dezortova, 2008], which is especially requested in the
more superior regions of the white matter along the CST.
The main message coming from this finding is that a com-
prehensive assessment of metabolic damage in patients
with MS has to pay attention to the spatial variation of the
metabolite concentrations along a tract, which may
improve the ability to distinguish pathological from
healthy tissue using imaging.
When we investigated the associations between metabo-
lite levels and disability, we found that, in the whole
group of patients, a lower Cho concentration was associ-
ated with worse walking ability, as measured by the TWT.
In the PPMS group, a lower Cho concentration correlated
with greater disability, as measured by the EDSS. These
associations suggest that membrane turnover associated
with inflammation, as reflected by Cho concentration, may
be lower in patients with greater disability. Since we
included the amount of lesional tissue within a voxel as a
covariate in all our analyses, it is unlikely that the pres-
ence of fewer lesions in the PPMS group has significantly
contributed to this finding. This is in agreement with
recent neuropathological evidence for less pronounced
inflammation in the normal-appearing WM in the later
phases of the progressive stage of the disease, where the
inflammatory infiltrates of T, B, and plasmatic cells seem
to be reduced when compared with those seen in earlier
stages of the disease [Frischer et al., 2009]. However,
extensive microglia activation, behind a closed or repaired
blood brain barrier, has been described in progressive MS
cases [Frischer et al., 2009; Moll et al., 2011]. It is known
that activated microglia show changes in both morphology
and expression of cell surface antigens [Ransohoff and
Perry, 2009]; these glial changes may not have a major
impact on the Cho concentration, because they may not
induce changes in membrane turnover. It would be impor-
tant to improve our understanding of what underlying
pathological processes are responsible for Cho signal
change in MS. Interestingly, the association between Cho
and TWT became stronger when the spatial variation of
this metabolite concentration was taken into account, sug-
gesting that attention to spatial variation permits the iden-
tification of metabolic changes that are clinically relevant.
In patients with PPMS we also detected a significant
association between lower Cr concentration and higher
EDSS, which may suggest that a less intact energy metabo-
lism, as reflected by Cr [Wyss and Kaddurah-Daouk, 2000]
has a negative effect on clinical disability. This is in line
with the recent hypothesis that energy metabolism, which
originates in the mitochondria, plays an important role in
the pathogenesis of MS [Di et al., 2010] and in determining
disability in MS [Ciccarelli et al., 2010a,b]. Interestingly,
greater levels of Cr have also been associated with glial
proliferation [Suhy et al., 2000], and we found greater Ins
in RRMS than PPMS. Previous studies have reported an
association between lower Cr concentration in the cortical
GM and greater disability in patients with RRMS [Chard
et al., 2002], and we have now extended these results to
the CST and patients with PPMS. In addition, in patients
with RRMS, we reported a significant, albeit modest, asso-
ciation between greater Ins concentration and greater dis-
ability, as measured by the TWT, suggesting that gliosis
may be a pathological process of clinical relevance in the
relapsing forms of MS [Kirov et al., 2009].
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Although we hypothesized that patients with PPMS
would show lower NAA than RRMS and healthy controls,
because of histological findings [Tallantyre et al., 2009],
and previous imaging investigations [Chard et al., 2002;
Ciccarelli et al., 2007, 2010a,b; Sastre-Garriga et al., 2005;
Suhy et al., 2000], we did not detect significant differences
in tNAA levels between groups. This may due to the fact
that we used a different CSI protocol and analysis, and
included MS patients with different characteristics. Addi-
tionally, we found a relatively large variability in tNAA
concentration that could have contributed to the lack of
tNAA concentration differences in terms of tNAA differen-
ces between groups, because it was much larger than the
difference in tNAA between groups (10% vs. 5%). The
observed SDs associated with mean tNAA concentrations
were indeed higher than those previously reported by
other authors [Chard et al., 2002; Sastre-Garriga et al.,
2005]. This variability in tNAA concentration could be due
to the fact that we entered in the statistical analysis all the
available voxels obtained along the CST (i.e., in different
regions of the tract) at the same time. Our analysis has
demonstrated that the tNAA concentration increased from
the inferior voxels towards the corona radiata, even when
correcting for the WM fraction, which also changed across
the CST. Therefore, this variability in tNAA levels can be
reduced by grouping voxels located in the same region
within a tract (as shown in the Supporting Information
Table I). Additionally, we performed a sample size calcula-
tion to estimate the number of subjects needed to detect
(with 80% power at 5% significance) a difference in tNAA
concentration of 4–5% (as observed in our study) between
patients and controls, using the means and SDs of tNAA
concentrations provided by our data, and standard meth-
ods for comparisons of means [Armitage et al., 2002]. We
found that relatively large sample sizes would be required
to detect significant tNAA differences (68 RRMS and 68
controls; over 98 PPMS patients and 98 controls). The
metabolite-specific reliability of fit can be guaranteed by
selecting only those metabolites that fall below the 20%
Cramer-Rao Lower Bound (CRLB) upper limit (see Sup-
porting Information Table II). From a methodological point
of view, an increase in TE might increase the chance of
finding significant differences in tNAA levels between
groups, since a previous meta-analysis has shown that
studies with TE < 90 ms tended to show no significant dif-
ferences in tNAA levels between MS patients and controls
[Caramanos et al., 2005]. Potential improvements in the
technique that would lead to a better quantification of
tNAA and include a higher field strength (3 T), better
shimming and a greater acquisition matrix size to reduce
the point spread function (PSF), may also contribute to
reduce the variability in tNAA concentration.
A technical limitation of CSI studies is that the PSF con-
tributes to the definition of the voxel size and should be
taken into account by evaluating the contamination to the
voxel of interest originating from voxels at neighboring
positions. In particular, it is known that the limited
sampling size of the CSI grid has a broadening effect on
the PSF, which means that the actual voxel size measured
at the FWHM may be larger than the prescribed one [Jan-
sen et al., 2006], and that the prescribed voxel is therefore
contributing to less than 100% of the measured signal at
each voxel position. In this study we examined the pre-
scribed voxel, without evaluating the effect of the PSF, and
it is therefore possible that partial volume effects from
neighboring voxels may have contributed to the observed
metabolite concentrations. Future CSI studies should con-
sider the possibility of improving the PSF during data ac-
quisition or postprocessing.
In addition, our statistical approach was very conserva-
tive, and adjusted for several variables, and the number of
patients in each group was relatively low. A possible limi-
tation of this study is that voxels may contain a very small
percentage of GM (or lesional tissue) in addition to WM,
which is unavoidable when performing CSI. To correct for
the possible contribution to the metabolite concentrations
originating of different amounts of tissues in each voxel,
we corrected all our statistical analysis for the tissue seg-
ment fractions calculated within each voxel.
In conclusion, the application of CSI to coronal-oblique
slices provides insights into the pathological processes in
the CST that are related to disability in RRMS and PPMS.
Our results also confirm that taking account of the spatial
variation that may exist in the concentration of the metab-
olites along WM tracts [Goldsmith et al., 2011] improves
the ability to detect differences in Cr between patients and
controls and significant correlations between Cho and clin-
ical disability. From a technical point of view, we
employed an innovative CSI methodology that could be
useful in future studies in MS or other neurological
disease to quantify metabolite concentrations along the
main WM tracts in the brain, and formulate location-spe-
cific hypotheses.
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